Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

AGNC Investment Corp AGNC

Alternate Symbol(s):  AGNCN

AGNC Investment Corp. is an internally managed real estate investment trust (REIT). The Company provides private capital to the United States housing market, enhancing liquidity in the residential real estate mortgage markets and, in turn, facilitating home ownership in the United States. The Company invest primarily in Agency residential mortgage-backed securities (Agency RMBS) on a leveraged basis. These investments consist of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a United States Government-sponsored enterprise, such as the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac, and together with Fannie Mae, the GSEs), or by a United States Government agency, such as the Government National Mortgage Association (Ginnie Mae). It may also invest in other assets related to the housing, mortgage or real estate markets.


NDAQ:AGNC - Post by User

Post by biggonadson Nov 17, 2022 2:53pm
139 Views
Post# 35108017

Progress from AGN DMT clinical stroke research program

Progress from AGN DMT clinical stroke research programAlgernon Pharmaceuticals announces that they’ve initiated their DMT clinical stroke research program with their Phase 1 study in the Netherlands. The release today indicates the progress of this clinical trial with the screening of its first subjects for the phase 1 DMT human stroke study. As multiple DMT phase 1 studies have already been conducted, the company expects no serious adverse events or safety issues which will lead to an effective transition into phase 2 acute stroke and rehab studies. https://www.globenewswire.com/news-release/2022/11/16/2557039/0/en/algernon-pharmaceuticals-screens-first-subject-in-phase-1-dmt-human-stroke-study.html
<< Previous
Bullboard Posts
Next >>